Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment

Diabetes mellitus (DM) is a global epidemic followed by late complications as diabetic polyneuropathy (DPN) and diabetic foot syndrome, leading to appreciable social and economic consequences. Virtually all patients with DM develop DPN in different periods. There is a clear correlation between the p...

Full description

Bibliographic Details
Main Authors: Marina Valentinovna Nesterova, V V Galkin
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2013-11-01
Series:Nevrologiâ, Nejropsihiatriâ, Psihosomatika
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/201
id doaj-d6d0227d69264e61bd4bbf9cd1ff605d
record_format Article
spelling doaj-d6d0227d69264e61bd4bbf9cd1ff605d2021-07-29T08:58:34ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422013-11-01529710510.14412/2074-2711-2013-2422201Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatmentMarina Valentinovna NesterovaV V GalkinDiabetes mellitus (DM) is a global epidemic followed by late complications as diabetic polyneuropathy (DPN) and diabetic foot syndrome, leading to appreciable social and economic consequences. Virtually all patients with DM develop DPN in different periods. There is a clear correlation between the presence and magnitude of painful DPN and the duration of DM and the level of glycosylated hemoglobin and the severity of DPN. In spite of the abundance of theories of the development of DPN, its main identified pathogenetic factor is hyperglycemia. The literature gives no universal classification due to the variability of clinical symptoms. The main goals of treatment are to affect the pathogenesis of the disease and to prescribe symptomatic medications. The pathogenetic treatment of DPN includes compensation for carbohydrate metabolism and use of neurometabolic drugs. Pain from DPN may be controlled with antidepressants, anticonvulsants, local anesthetics and opioid analgesics. Although much evidence for the pathogenesis of peripheral nervous system injury has been recently accumulated, a universal standard for the effective therapy of DPN and the follow-up of these patients has not yet been developed.https://nnp.ima-press.net/nnp/article/view/201diabetes mellitusdiabetic polyneuropathypainful syndrome
collection DOAJ
language Russian
format Article
sources DOAJ
author Marina Valentinovna Nesterova
V V Galkin
spellingShingle Marina Valentinovna Nesterova
V V Galkin
Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
Nevrologiâ, Nejropsihiatriâ, Psihosomatika
diabetes mellitus
diabetic polyneuropathy
painful syndrome
author_facet Marina Valentinovna Nesterova
V V Galkin
author_sort Marina Valentinovna Nesterova
title Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
title_short Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
title_full Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
title_fullStr Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
title_full_unstemmed Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
title_sort diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment
publisher IMA-PRESS LLC
series Nevrologiâ, Nejropsihiatriâ, Psihosomatika
issn 2074-2711
2310-1342
publishDate 2013-11-01
description Diabetes mellitus (DM) is a global epidemic followed by late complications as diabetic polyneuropathy (DPN) and diabetic foot syndrome, leading to appreciable social and economic consequences. Virtually all patients with DM develop DPN in different periods. There is a clear correlation between the presence and magnitude of painful DPN and the duration of DM and the level of glycosylated hemoglobin and the severity of DPN. In spite of the abundance of theories of the development of DPN, its main identified pathogenetic factor is hyperglycemia. The literature gives no universal classification due to the variability of clinical symptoms. The main goals of treatment are to affect the pathogenesis of the disease and to prescribe symptomatic medications. The pathogenetic treatment of DPN includes compensation for carbohydrate metabolism and use of neurometabolic drugs. Pain from DPN may be controlled with antidepressants, anticonvulsants, local anesthetics and opioid analgesics. Although much evidence for the pathogenesis of peripheral nervous system injury has been recently accumulated, a universal standard for the effective therapy of DPN and the follow-up of these patients has not yet been developed.
topic diabetes mellitus
diabetic polyneuropathy
painful syndrome
url https://nnp.ima-press.net/nnp/article/view/201
work_keys_str_mv AT marinavalentinovnanesterova diabeticpolyneuropathypathogenesisclassificationclinicalpresentationandtreatment
AT vvgalkin diabeticpolyneuropathypathogenesisclassificationclinicalpresentationandtreatment
_version_ 1721250778428997632